Variant surface glycoprotein (VSG)

Variant surface glycoprotein (VSG) is the primary surface protein of Trypanosoma brucei, the protozoan parasite responsible for African trypanosomiasis, also known as sleeping sickness [1]. It forms a dense homodimeric coat that covers the entire plasma membrane of the parasite, acting as a physical shield against the host's innate immune system and preventing lysis by the alternative complement pathway [5]. The most critical biological feature of VSG is its role in antigenic variation, where the parasite periodically switches the expression of its VSG gene from a genomic repertoire of over 1,000 variants [2]. This process allows the parasite to evade the host's adaptive immune response, leading to persistent infection and the characteristic waves of parasitemia observed in clinical cases [6]. In the context of therapeutics, VSG is the primary target for the host's humoral immune response and serves as the basis for diagnostic tools like the Card Agglutination Test for Trypanosomiasis (CATT) [3]. While current clinical treatments such as fexinidazole, suramin, and pentamidine do not target VSG directly—instead focusing on the parasite's internal metabolic and replicative processes—VSG remains a major focus for experimental drug development [1]. Research into nanobodies and small molecules that can disrupt the VSG coat or inhibit its anchoring mechanism is ongoing to overcome the challenges posed by the parasite's rapid antigenic switching [4].

Other names

VSGSurface antigenTrypanosome variant surface glycoproteinVariable surface glycoprotein

Currently, there are no approved drugs that directly target the Variant surface glycoprotein (VSG). Clinical treatments for African trypanosomiasis, such as fexinidazole and suramin, target the parasite's internal metabolic pathways. However, VSG is the primary target of the host's humoral immune response, and experimental strategies involve using nanobodies (e.g., NbAn33) to disrupt the VSG coat or targeting the glycosylphosphatidylinositol (GPI) biosynthetic pathway to prevent VSG from anchoring to the parasite surface [1, 4, 6].